Loading
The one UK study to look found young Black women had more triple-negative breast cancer and worse survival than White women despite equal chemotherapy, but it ended in 2008 and covered women under 41. Routine cancer statistics could report triple-negative incidence, stage and survival by ethnicity every year; at present they do not.
Placeholder for the UK-specific gaps named on the UK and NHS page for triple-negative breast cancer. The POSH cohort (2,915 women aged 40 or under, recruited 2000 to 2008) found triple-negative disease in 26.1 percent of Black against 18.6 percent of White women, larger tumours at presentation, and five-year overall survival of 71.1 versus 82.4 percent with chemotherapy use equal at about 89 percent; Black ethnicity was an independent risk factor for distant relapse. United States registries have reported triple-negative incidence by ethnicity since 2010. English cancer registration records receptor status and ethnicity but does not publish triple-negative outcomes by ethnicity, so whether the POSH gap persists in the immunotherapy era, whether it extends to older women, and whether it reflects stage at diagnosis, germline variants, subtype or treatment delivery is unknown.
The most recent national figure behind the statement that Black women in the United States have about twice the incidence of triple-negative breast cancer; trial enrolment has not matched it.
The UK's own evidence that the disparity is not only American and not only about access: within the NHS, with equal chemotherapy use, young Black women had more triple-negative disease and worse survival. It anchors the disparities idea on the triple-negative page and the UK and NHS page.
The denominator for US triple-negative disparity statistics and the origin of the 10 to 15 percent figure quoted for the subtype's share of breast cancer.
Shares Update on triple-negative breast cancer disparities for the United States: A population-based study from the United States Cancer Statistics database, 2010 through 2014, Close the gap between who gets triple-negative breast cancer and who is in its trials, Trials do not represent the people who get cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study, Close the gap between who gets triple-negative breast cancer and who is in its trials, Fragmented care and guideline gaps, Data silos and the tag tnbc-evidence.
Shares Ethnicity and outcome of young breast cancer patients in the United Kingdom: the POSH study, Close the gap between who gets triple-negative breast cancer and who is in its trials, Trials do not represent the people who get cancer, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem and the tag tnbc-evidence.
Shares Cancer Research UK, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Cancer Research UK, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.
Shares Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC) and the tag tnbc-evidence.